Propafenone for the treatment of supraventricular tachycardia and atrial fibrillation: A meta-analysis

S. C. Reimold, W. H. Maisel, E. M. Antman, J. A. Reiffel, S. C. Reimold

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

The purpose of this study was to determine propafenone's effectiveness in terminating and suppressing supraventricular arrhythmias using meta- analytic techniques. Published abstracts and manuscripts with these goals were selected and data abstracted on conversion and maintenance of sinus rhythm. Data were pooled using standard meta-analytic techniques and analyzed according to observation times, trial design (randomized versus nonrandomized), and route of drug administration. Propafenone successfully terminated 83.8% (95% confidence interval 78.1-89.7%) of supraventricular tachycardias. For supraventricular tachycardias, the proportion of patients remaining in sinus rhythm without recurrent arrhythmia was 64.6% (58.1- 71.1%) at 1 year. The likelihood of converting a paroxysm of atrial fibrillation (AF) increased over time, with 76.1% (72.8-79.4%) of patients in sinus rhythm 24 hours after initiation of therapy. Patients receiving intravenous therapy were more likely to convert to sinus rhythm in the first 4 hours after drug administration. The treatment benefit of propafenone versus placebo in converting sinus rhythm was greatest in the first 8 hours after treatment (treatment benefit of 31.5% [24.5-38.5%] at 4 hours and 32.9% [24.3-41.5%] at 8 hours, p <0.01). This treatment benefit decreased to 11.0% (-0.6-22.4%) after 24 hours. Propafenone was effective in suppressing recurrences of AF in 55.4% (51.3-59.7%) at 6 months and 56.8% (52.3-61.3%) at 12 months. Thus, propafenone is effective in terminating supraventricular tachycardias and AF in the vast majority of patients. Suppression of arrhythmia recurrences is feasible in most patients, although its effectiveness decreases over time.

Original languageEnglish (US)
JournalAmerican Journal of Cardiology
Volume82
Issue number8 A
StatePublished - 1998

Fingerprint

Propafenone
Supraventricular Tachycardia
Atrial Fibrillation
Meta-Analysis
Cardiac Arrhythmias
Therapeutics
Drug Administration Routes
Recurrence
Manuscripts
Placebos
Maintenance
Observation
Confidence Intervals
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Propafenone for the treatment of supraventricular tachycardia and atrial fibrillation : A meta-analysis. / Reimold, S. C.; Maisel, W. H.; Antman, E. M.; Reiffel, J. A.; Reimold, S. C.

In: American Journal of Cardiology, Vol. 82, No. 8 A, 1998.

Research output: Contribution to journalArticle

Reimold, S. C. ; Maisel, W. H. ; Antman, E. M. ; Reiffel, J. A. ; Reimold, S. C. / Propafenone for the treatment of supraventricular tachycardia and atrial fibrillation : A meta-analysis. In: American Journal of Cardiology. 1998 ; Vol. 82, No. 8 A.
@article{100ccf7539814f5aa31f48757f13e191,
title = "Propafenone for the treatment of supraventricular tachycardia and atrial fibrillation: A meta-analysis",
abstract = "The purpose of this study was to determine propafenone's effectiveness in terminating and suppressing supraventricular arrhythmias using meta- analytic techniques. Published abstracts and manuscripts with these goals were selected and data abstracted on conversion and maintenance of sinus rhythm. Data were pooled using standard meta-analytic techniques and analyzed according to observation times, trial design (randomized versus nonrandomized), and route of drug administration. Propafenone successfully terminated 83.8{\%} (95{\%} confidence interval 78.1-89.7{\%}) of supraventricular tachycardias. For supraventricular tachycardias, the proportion of patients remaining in sinus rhythm without recurrent arrhythmia was 64.6{\%} (58.1- 71.1{\%}) at 1 year. The likelihood of converting a paroxysm of atrial fibrillation (AF) increased over time, with 76.1{\%} (72.8-79.4{\%}) of patients in sinus rhythm 24 hours after initiation of therapy. Patients receiving intravenous therapy were more likely to convert to sinus rhythm in the first 4 hours after drug administration. The treatment benefit of propafenone versus placebo in converting sinus rhythm was greatest in the first 8 hours after treatment (treatment benefit of 31.5{\%} [24.5-38.5{\%}] at 4 hours and 32.9{\%} [24.3-41.5{\%}] at 8 hours, p <0.01). This treatment benefit decreased to 11.0{\%} (-0.6-22.4{\%}) after 24 hours. Propafenone was effective in suppressing recurrences of AF in 55.4{\%} (51.3-59.7{\%}) at 6 months and 56.8{\%} (52.3-61.3{\%}) at 12 months. Thus, propafenone is effective in terminating supraventricular tachycardias and AF in the vast majority of patients. Suppression of arrhythmia recurrences is feasible in most patients, although its effectiveness decreases over time.",
author = "Reimold, {S. C.} and Maisel, {W. H.} and Antman, {E. M.} and Reiffel, {J. A.} and Reimold, {S. C.}",
year = "1998",
language = "English (US)",
volume = "82",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "8 A",

}

TY - JOUR

T1 - Propafenone for the treatment of supraventricular tachycardia and atrial fibrillation

T2 - A meta-analysis

AU - Reimold, S. C.

AU - Maisel, W. H.

AU - Antman, E. M.

AU - Reiffel, J. A.

AU - Reimold, S. C.

PY - 1998

Y1 - 1998

N2 - The purpose of this study was to determine propafenone's effectiveness in terminating and suppressing supraventricular arrhythmias using meta- analytic techniques. Published abstracts and manuscripts with these goals were selected and data abstracted on conversion and maintenance of sinus rhythm. Data were pooled using standard meta-analytic techniques and analyzed according to observation times, trial design (randomized versus nonrandomized), and route of drug administration. Propafenone successfully terminated 83.8% (95% confidence interval 78.1-89.7%) of supraventricular tachycardias. For supraventricular tachycardias, the proportion of patients remaining in sinus rhythm without recurrent arrhythmia was 64.6% (58.1- 71.1%) at 1 year. The likelihood of converting a paroxysm of atrial fibrillation (AF) increased over time, with 76.1% (72.8-79.4%) of patients in sinus rhythm 24 hours after initiation of therapy. Patients receiving intravenous therapy were more likely to convert to sinus rhythm in the first 4 hours after drug administration. The treatment benefit of propafenone versus placebo in converting sinus rhythm was greatest in the first 8 hours after treatment (treatment benefit of 31.5% [24.5-38.5%] at 4 hours and 32.9% [24.3-41.5%] at 8 hours, p <0.01). This treatment benefit decreased to 11.0% (-0.6-22.4%) after 24 hours. Propafenone was effective in suppressing recurrences of AF in 55.4% (51.3-59.7%) at 6 months and 56.8% (52.3-61.3%) at 12 months. Thus, propafenone is effective in terminating supraventricular tachycardias and AF in the vast majority of patients. Suppression of arrhythmia recurrences is feasible in most patients, although its effectiveness decreases over time.

AB - The purpose of this study was to determine propafenone's effectiveness in terminating and suppressing supraventricular arrhythmias using meta- analytic techniques. Published abstracts and manuscripts with these goals were selected and data abstracted on conversion and maintenance of sinus rhythm. Data were pooled using standard meta-analytic techniques and analyzed according to observation times, trial design (randomized versus nonrandomized), and route of drug administration. Propafenone successfully terminated 83.8% (95% confidence interval 78.1-89.7%) of supraventricular tachycardias. For supraventricular tachycardias, the proportion of patients remaining in sinus rhythm without recurrent arrhythmia was 64.6% (58.1- 71.1%) at 1 year. The likelihood of converting a paroxysm of atrial fibrillation (AF) increased over time, with 76.1% (72.8-79.4%) of patients in sinus rhythm 24 hours after initiation of therapy. Patients receiving intravenous therapy were more likely to convert to sinus rhythm in the first 4 hours after drug administration. The treatment benefit of propafenone versus placebo in converting sinus rhythm was greatest in the first 8 hours after treatment (treatment benefit of 31.5% [24.5-38.5%] at 4 hours and 32.9% [24.3-41.5%] at 8 hours, p <0.01). This treatment benefit decreased to 11.0% (-0.6-22.4%) after 24 hours. Propafenone was effective in suppressing recurrences of AF in 55.4% (51.3-59.7%) at 6 months and 56.8% (52.3-61.3%) at 12 months. Thus, propafenone is effective in terminating supraventricular tachycardias and AF in the vast majority of patients. Suppression of arrhythmia recurrences is feasible in most patients, although its effectiveness decreases over time.

UR - http://www.scopus.com/inward/record.url?scp=0031766856&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031766856&partnerID=8YFLogxK

M3 - Article

C2 - 9809903

AN - SCOPUS:0031766856

VL - 82

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 8 A

ER -